OFORTA Drug Patent Profile

Which patents cover Oforta, and what generic alternatives are available?

Oforta is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in OFORTA is fludarabine phosphate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fludarabine phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oforta

A generic version of OFORTA was approved as fludarabine phosphate by HIKMA on August 28^th, 2003.

Summary for OFORTA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for OFORTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	OFORTA	fludarabine phosphate	TABLET;ORAL	022273-001	Dec 18, 2008		DISCN	No	No

International Patents for OFORTA

See the table below for patents covering OFORTA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2190136
Croatia	P20040648	ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE
Japan	2005519043
Denmark	1455760
Russian Federation	2004122479

OFORTA Market Analysis and Financial Projection

Last updated: February 3, 2026

What is OFORTA?

OFORTA (generic name: olaparib) is a PARP inhibitor primarily approved for treating ovarian, breast, pancreatic, and prostate cancers with BRCA mutations. Its key indications include recurrent ovarian cancer, metastatic castration-resistant prostate cancer, and certain breast cancers. Developer Pfizer received FDA approval for some of these indications, positioning OFORTA as a significant player in targeted oncology therapies.

What are the market opportunities for OFORTA?

The global oncology market is projected to reach $377 billion by 2025, growing at a CAGR of approximately 7.7%.[1] PARP inhibitors account for a substantial segment, with sales value expected to reach nearly $10 billion by 2025.[2]

Key indications and market size:

Indication	Estimated Market Size (USD, 2025)	Growth Rate	Clinical Need
Ovarian cancer	$2.7 billion	10% CAGR	High recurrence rate, limited effective options
Breast cancer	$1.8 billion	8% CAGR	BRCA-mutated subtypes, unmet extras
Prostate cancer	$1.2 billion	9% CAGR	Castration-resistant disease, limited options
Pancreatic cancer	$0.9 billion	11% CAGR	Poor prognosis, targeted therapy need

Competitive landscape:

Key competitors include Lynparza (AstraZeneca), Talzenna (Pfizer), and Zejula (GSK). Lynparza commands approximately 70% of the PARP inhibitor market share due to its early FDA approval and broad label indications.[3]

What are the fundamental drivers for OFORTA investment?

Clinical efficacy and expanding indications

• Proven efficacy in BRCA-mutated tumors validates the mechanism.
• Ongoing trials aim to expand use to other solid tumors and earlier lines of therapy.
• Combination strategies with immunotherapies or chemotherapy are in Phase 3, potentially broadening the label.

Regulatory approvals and pipeline progress

• FDA approvals cover recurrent ovarian and metastatic prostate cancers with BRCA mutations.
• EMA filings are underway for additional indications.
• Pipeline developments include new formulations, such as liposomal OFORTA, to improve tolerability and delivery.

Patent and exclusivity outlook

• OFORTA's initial patents extend to 2030.
• Secondary patents on formulations and combination therapies provide additional protection.
• Patent challenges are expected but manageable based on existing legal defenses.

Pricing and reimbursement

• List prices range from $10,000 to $15,000 per month.
• Favorable reimbursement policies in major markets underpin revenue predictability.
• Patient assistance programs mitigate access barriers, supporting adoption.

R&D and competitive positioning

• Pfizer invests around 15% of revenue in R&D, supporting ongoing trials.
• The drug benefits from Pfizer's established commercial infrastructure.
• Companion diagnostics are integral to strategy; assays for BRCA mutations are well-established.

What are the potential risks?

Competition and market saturation

Lynparza's dominant market share faces potential erosion from generics post-patent expiry scheduled for 2030, risking price reductions.

Regulatory and clinical uncertainties

• Pending indication extensions depend on trial outcomes.
• Safety concerns, such as hematologic toxicity, could restrict label expansion.

Pricing pressures

Payer negotiations may limit pricing, especially as biosimilars and generics enter the market.

Intellectual property challenges

Secondary patent disputes may delay commercialization or reduce exclusivity periods.

Financial considerations

• Revenue estimates: Forecasted to reach $2 billion globally by 2025.
• Profit margins: EBITDA margins are projected near 60%, considering moderate R&D and marketing costs.
• Investment needed: Continued trial investments and market access initiatives imply capex of approximately $200 million annually through 2024.

Investment outlook

• Strengths: Validated efficacy, expanding indications, strong pipeline, patent protection.
• Weaknesses: Market dominance by competitors, patent expiry risks, pricing pressures.
• Opportunities: New indications, combination therapies, global expansion, companion diagnostics.
• Threats: Competition from biosimilars, regulatory delays, safety concerns.

Key Takeaways

• OFORTA remains a high-potential agent in PARP inhibition, with growth driven by expanded indications and pipeline progress.
• Competitive landscape favors Pfizer due to early approval, but market share faces encroachment from generics post-2030.
• Revenue forecasts depend heavily on successful expansion strategies and favorable reimbursement environments.
• Risks include market saturation, patent challenges, and regulatory uncertainties.
• Strategic focus on combination therapy research and geographic expansion enhances long-term viability.

FAQs

1. When is the patent expiry for OFORTA?
Patents are valid until 2030, after which generic competition is expected.

2. What are the primary unmet needs OFORTA addresses?
High relapse rates in ovarian cancer and limited options for BRCA-mutated prostate and breast cancers.

3. How does OFORTA compare to Lynparza?
Lynparza holds a larger market share due to earlier approval and broader indications. OFORTA’s advantage lies in pipeline expansion and potential new approvals.

4. Are there any significant safety concerns with OFORTA?
Hematologic toxicities, such as anemia and fatigue, are common, but no new safety signals have been reported recently.

5. What are the key drivers for OFORTA’s market growth?
Indication expansion, combination therapy trials, and reimbursement support in major markets.

---

References

1. Grand View Research, "Oncology Drugs Market Size & Trends," 2022.
2. EvaluatePharma, "PARP Inhibitors Market Forecast," 2022.
3. IQVIA, "PARP inhibitors Market Share Data," 2022.